Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension

Quynh N Dinh, Grant R Drummond, Christopher G Sobey, Sophocles Chrissobolis, Quynh N Dinh, Grant R Drummond, Christopher G Sobey, Sophocles Chrissobolis

Abstract

Hypertension is a complex condition and is the most common cardiovascular risk factor, contributing to widespread morbidity and mortality. Approximately 90% of hypertension cases are classified as essential hypertension, where the precise cause is unknown. Hypertension is associated with inflammation; however, whether inflammation is a cause or effect of hypertension is not well understood. The purpose of this review is to describe evidence from human and animal studies that inflammation leads to the development of hypertension, as well as the evidence for involvement of oxidative stress and endothelial dysfunction--both thought to be key steps in the development of hypertension. Other potential proinflammatory conditions that contribute to hypertension-such as activation of the sympathetic nervous system, aging, and elevated aldosterone--are also discussed. Finally, we consider the potential benefit of anti-inflammatory drugs and statins for antihypertensive therapy. The evidence reviewed suggests that inflammation can lead to the development of hypertension and that oxidative stress and endothelial dysfunction are involved in the inflammatory cascade. Aging and aldosterone may also both be involved in inflammation and hypertension. Hence, in the absence of serious side effects, anti-inflammatory drugs could potentially be used to treat hypertension in the future.

Figures

Figure 1
Figure 1
Schematic diagram illustrating the relationship between inflammation and hypertension and the contributing factors involved. Anti-inflammatory drugs and statins may be effective antihypertensive due to their anti-inflammatory properties.
Figure 2
Figure 2
(a) Diagram illustrating endothelium-dependent relaxation during health. (b) Diagram illustrating mechanism by which inflammation and oxidative stress cause endothelial dysfunction. Inflammatory mediators such as CRP and TNF destabilise eNOS mRNA (thus inhibiting eNOS). NO protects endothelium by inhibiting leukocyte adhesion; thus, impaired NO function results in increased leukocyte adhesion. Increased superoxide (derived from NADPH oxidase or uncoupled eNOS) impairs NO bioavailability and leads to impaired vascular relaxation. The figure is based on text.

References

    1. Ventura HO, Taler SJ, Strobeck JE. Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. The American Journal of Hypertension. 2005;18(2):26S–43S.
    1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. The Lancet. 2005;365(9455):217–223.
    1. Messerli FH, Williams B, Ritz E. Essential hypertension. The Lancet. 2007;370(9587):591–603.
    1. Onusko E. Diagnosing secondary hypertension. The American Family Physician. 2003;67(1):67–74.
    1. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. The Lancet. 2003;362(9395):1527–1535.
    1. Bhanot S, McNeill JH. Insulin and hypertension: a causal relationship? Cardiovascular Research. 1996;31(2):212–221.
    1. Tran LT, Yuen VG, McNeill JH. The fructose-fed rat: a review on the mechanisms of fructose-induced insulin resistance and hypertension. Molecular and Cellular Biochemistry. 2009;332(1-2):145–159.
    1. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–194.
    1. Keane MP, Strieter RM. Chemokine signaling in inflammation. Critical Care Medicine. 2000;28(4):N13–N26.
    1. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241.
    1. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. International Journal of Biochemistry and Cell Biology. 2004;36(3):372–378.
    1. Asanuma YF. Accelerated atherosclerosis and inflammation in systemic lupus erythematosus. Japanese Journal of Clinical Immunology. 2012;35(6):470–480.
    1. Mortensen RF, Zhong W. Regulation of phagocytic leukocyte activities by C-reactive protein. Journal of Leukocyte Biology. 2000;67(4):495–500.
    1. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4(5):361–368.
    1. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102(18):2165–2168.
    1. Stumpf C, Jukic J, Yilmaz A, et al. Elevated VEGF-plasma levels in young patients with mild essential hypertension. European Journal of Clinical Investigation. 2009;39(1):31–36.
    1. Bautista LE, Atwood JE, O'Malley PG, Taylor AJ. Association between C-reactive protein and hypertension in healthy middle-aged men and women. Coronary Artery Disease. 2004;15(6):331–336.
    1. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108(24):2993–2999.
    1. Stuveling EM, Bakker SJL, Hillege HL, et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension. 2004;43(4):791–796.
    1. Sung KC, Suh JY, Kim BS, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. American Journal of Hypertension. 2003;16(6):429–433.
    1. Xu T, Ju Z, Tong W, et al. Relationship of C-reactive protein with hypertension and interactions between increased C-reactive protein and other risk factors on hypertension in Mongolian people, China. Circulation Journal. 2008;72(8):1324–1328.
    1. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. The American Journal of Hypertension. 2004;17(7):568–573.
    1. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. Journal of the American Medical Association. 2003;290(22):2945–2951.
    1. Dauphinot V, Roche F, Kossovsky MP, et al. C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof study. Journal of Hypertension. 2009;27(4):736–743.
    1. Niskanen L, Laaksonen DE, Nyyssönen K, et al. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension. 2004;44(6):859–865.
    1. Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediators of Inflammation. 2010;2010585989
    1. Lieb W, Pencina MJ, Wang TJ, et al. Association of parental hypertension with concentrations of select biomarkers in nonhypertensive offspring. Hypertension. 2008;52(2):381–386.
    1. Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. Journal of Human Hypertension. 2005;19(2):149–154.
    1. Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in apparently healthy men. Hypertension. 2001;38(3):399–403.
    1. Fernandez-Real J-M, Vayreda M, Richart C, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. The Journal of Clinical Endocrinology & Metabolism. 2001;86(3):1154–1159.
    1. Zhao S, Li Q, Liu L, Xu Z, Xiao J. Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension. Clinica Chimica Acta. 2004;344(1-2):195–200.
    1. Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC. Increased serum levels of interleukin-1β in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? Journal of Laboratory and Clinical Medicine. 1997;129(3):300–308.
    1. Yu X, Yang Z, Yu M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage. Renal Failure. 2010;32(4):475–479.
    1. Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A. Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early atherosclerosis. Hypertension Research. 2002;25(3):475–480.
    1. Youn J, Yu HT, Lim BJ, et al. Immunosenescent CD8+ T clls and C-X-C cemokine receptor type 3 chemokines are increased in human hypertension. Hypertension. 2013;62(1):126–133.
    1. Seaberg EC, Muñoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19(9):953–960.
    1. Hodyl NA, Stark MJ, Osei-Kumah A, Clifton VL. Prenatal programming of the innate immune response following in utero exposure to inflammation: a sexually dimorphic process? Expert Review of Clinical Immunology. 2011;7(5):579–592.
    1. Msall ME, Buck GM, Rogers BT, et al. Multivariate risks among extremely premature infants. Journal of Perinatology. 1994;14(1):41–47.
    1. Mwanyumba F, Inion I, Gaillard P, Mandaliya K, Praet M, Temmerman M. Placental inflammation and perinatal outcome. European Journal of Obstetrics Gynecology and Reproductive Biology. 2003;108(2):164–170.
    1. Rodríguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial inflammation and NF-κB activation in spontaneously hypertensive rats. American Journal of Nephrology. 2004;24(6):587–594.
    1. Waki H, Liu B, Miyake M, et al. Junctional adhesion molecule-1 is upregulated in spontaneously hypertensive rats: evidence for a prohypertensive role within the brain stem. Hypertension. 2007;49(6):1321–1327.
    1. De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25(10):2106–2113.
    1. Zhang W, Wang W, Yu H, et al. Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage. Hypertension. 2012;59(1):136–144.
    1. Sriramula S, Haque M, Majid DSA, Francis J. Involvement of tumor necrosis factor-α in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51(5):1345–1351.
    1. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010;55(2):500–507.
    1. Crosswhite P, Sun Z. Ribonucleic acid interference knockdown of interleukin 6 attenuates cold-induced hypertension. Hypertension. 2010;55(6):1484–1491.
    1. Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-κB prevents hypertension in spontaneously hypertensive rats. Journal of Pharmacology and Experimental Therapeutics. 2005;315(1):51–57.
    1. Wu KLH, Chan SHH, Chan JYH. Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. Journal of Neuroinflammation. 2012;9(1, article 212)
    1. Wei YL, Li XH, Zhou JZ. Prenatal exposure to lipopolysaccharide results in increases in blood pressure and body weight in rats. Acta Pharmacologica Sinica. 2007;28(5):651–656.
    1. Hao X-Q, Zhang H-G, Yuan Z-B, Yang D, Hao L, Li X. Prenatal exposure to lipopolysaccharide alters the intrarenal renin-angiotensin system and renal damage in offspring rats. Hypertension Research. 2010;33(1):76–82.
    1. Samuelsson A, Öhrn I, Dahlgren J, et al. Prenatal exposure to interleukin-6 results in hypertension and increased hypothalamic-pituitary-adrenal axis activity in adult rats. Endocrinology. 2004;145(11):4897–4911.
    1. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II-induced hypertension and vascular dysfunction. Journal of Experimental Medicine. 2007;204(10):2449–2460.
    1. Marvar PJ, Vinh A, Thabet S, et al. T lymphocytes and vascular inflammation contribute to stress-dependent hypertension. Biological Psychiatry. 2012;71(9):774–782.
    1. Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin ii-induced arterial hypertension and vascular dysfunction. Circulation. 2011;124(12):1370–1381.
    1. Jurewicz M, McDermott DH, Sechler JM, et al. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. Journal of the American Society of Nephrology. 2007;18(4):1093–1102.
    1. Hoch NE, Guzik TJ, Chen W, et al. Regulation of T-cell function by endogenously produced angiotensin II. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2009;296(2):R208–R216.
    1. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacological Reviews. 2000;52(1):11–34.
    1. Wang C, Li S, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107(13):1783–1790.
    1. Gurantz D, Cowling RT, Varki N, Frikovsky E, Moore CD, Greenberg BH. IL-1β and TNF-α upregulate angiotensin II type 1 (AT 1) receptors on cardiac fibroblasts and are associated with increased AT1 density in the post-MI heart. Journal of Molecular and Cellular Cardiology. 2005;38(3):505–515.
    1. Zhang ZH, Yu Y, Wei S, Felder RB. Centrally administered lipopolysaccharide elicits sympathetic excitation via NAD(P)H oxidase-dependent mitogen-activated protein kinase signaling. Journal of Hypertension. 2010;28(4):806–816.
    1. Trott DW, Harrison DG. The immune system in hypertension. Advances in Physiology Education. 2014;38(1):20–24.
    1. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–140.
    1. Chrissobolis S, Miller AA, Drummond GR, Kemp-Harper BK, Sobey CG. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Frontiers in Bioscience. 2011;16(5):1733–1745.
    1. Chrissobolis S, Faraci FM. The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trends in Molecular Medicine. 2008;14(11):495–502.
    1. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. Journal of Clinical Investigation. 1992;90(1):278–281.
    1. Verma S, Wang C, Li S, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106(8):913–919.
    1. Yan G, You B, Chen S, Liao JK, Sun J. Tumor necrosis factor-α downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1-α 1. Circulation Research. 2008;103(6):591–597.
    1. Mäki-Petäjä KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation. 2006;114(11):1185–1192.
    1. Nguyen H, Chiasson VL, Chatterjee P, Kopriva SE, Young KJ, Mitchell BM. Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension. Cardiovascular Research. 2013;97(4):696–704.
    1. Fleming I, Bauersachs J, Schafer A, Scholz D, Aldershvile J, Busse R. Isometric contraction induces the Ca2+-independent activation of the endothelial nitric oxidesynthase. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(3):1123–1128.
    1. Chrissobolis S, Sobey CG. Evidence that Rho-kinase activity contributes to cerebral vascular tone in vivo and is enhanced during chronic hypertension: comparison with protein kinase C. Circulation Research. 2001;88(8):774–779.
    1. Fichtlscherer S, Breuer S, Schächinger V, Dimmeler S, Zeiher AM. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. European Heart Journal. 2004;25(16):1412–1418.
    1. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(11):4651–4655.
    1. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circulation Research. 1995;76(6):980–986.
    1. Tomita H, Egashira K, Kubo-Inoue M, et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18(9):1456–1464.
    1. Qian H, Neplioueva V, Shetty GA, Channon KM, George SE. Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. Circulation. 1999;99(23):2979–2982.
    1. Crowley SD. The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antioxidants & Redox Signaling. 2014;20(1):102–120.
    1. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nature Reviews Drug Discovery. 2011;10(6):453–471.
    1. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells—implications in cardiovascular disease. Brazilian Journal of Medical and Biological Research. 2004;37(8):1263–1273.
    1. Huie RE, Padmaja S. The reaction of no with superoxide. Free Radical Research Communications. 1993;18(4):195–199.
    1. Cudd A, Fridovich I. Electrostatic interactions in the reaction mechanism of bovine erythrocyte superoxide dismutase. Journal of Biological Chemistry. 1982;257(19):11443–11447.
    1. Vásquez-Vivar J, Kalyanaraman B, Martásek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(16):9220–9225.
    1. Hassoun EA, Li F, Abushaban A, Stohs SJ. Production of superoxide anion, lipid peroxidation and DNA damage in the hepatic and brain tissues of rats after subchronic exposure to mixtures of TCDD and its congeners. Journal of Applied Toxicology. 2001;21(3):211–219.
    1. Canty TG, Jr., Boyle EM, Jr., Farr A, Morgan EN, Verrier ED, Pohlman TH. Oxidative stress induces NF-κB nuclear translocation without degradation of IκBα. Circulation. Circulation. 1999;100(19):II-361–II-364.
    1. Yasunari K, Maeda K, Nakamura M, Yoshikawa J. Oxidative stress in leukocytes is a possible link between blood pressure, blood glucose, and C-reacting protein. Hypertension. 2002;39(3):777–780.
    1. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. Journal of the American Society of Nephrology. 2007;18(10):2644–2648.
    1. Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. American Journal of Kidney Diseases. 2006;48(5):752–760.
    1. Stuveling EM, Hillege HL, Bakker SJL, Gans ROB, De Jong PE, De Zeeuw D. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney International. 2003;63(2):654–661.
    1. Biswas SK, de Faria JBL. Which comes first: renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radical Research. 2007;41(2):216–224.
    1. Lao D, Parasher PS, Cho KC, Yeghiazarians Y. Atherosclerotic renal artery stenosis—diagnosis and treatment. Mayo Clinic Proceedings. 2011;86(7):649–657.
    1. Khatami MR. Ischemic nephropathy: more than a simple renal artery narrowing. Iranian Journal of Kidney Diseases. 2013;7(2):82–100.
    1. Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study. Journal of Vascular Surgery. 2002;36(3):443–451.
    1. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine. 2011;17(11):1410–1422.
    1. Guyenet PG. The sympathetic control of blood pressure. Nature Reviews Neuroscience. 2006;7(5):335–346.
    1. Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension. 2004;43(2 I):169–175.
    1. Tan Z-Y, Lu Y, Whiteis CA, et al. Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR. Circulation Research. 2010;106(3):536–545.
    1. Nance DM, Sanders VM. Autonomic innervation and regulation of the immune system (1987–2007) Brain, Behavior, and Immunity. 2007;21(6):736–745.
    1. Lob HE, Marvar PJ, Guzik TJ, et al. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension. 2010;55(2):277–283.
    1. Veelken R, Vogel E, Hilgers K, et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. Journal of the American Society of Nephrology. 2008;19(7):1371–1378.
    1. Yu Y, Zhang Z, Wei S, Serrats J, Weiss RM, Felder RB. Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension. 2010;55(3):652–659.
    1. Bunag RD, Page IH, McCubbin JW. Neural stimulation of release of renin. Circulation Research. 1966;19(4):851–858.
    1. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the symplicity htn-2 randomized, controlled trial. Circulation. 2012;126(25):2976–2982.
    1. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. The New England Journal of Medicine. 2014;370(15):1393–1401.
    1. Krum H. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–917.
    1. Verheye S. TCT-62 preliminary result of the rapid renal sympathetic denervation for resistant hypertension using the maya medical OneShot(tm) Ablation System (RAPID) study. Journal of the American College of Cardiology. 2013;62(18, supplement 1):p. B20.
    1. Lloyd-Sherlock P, Beard J, Minicuci N, Ebrahim S, Chatterji S. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. International Journal of Epidemiology. 2014;43(1):116–128.
    1. van Rossum CTM, van de Mheen H, Witteman JCM, Hofman A, Mackenbach JP, Grobbee DE. Prevalence, treatment, and control of hypertension by sociodemographic factors among the Dutch elderly. Hypertension. 2000;35(3):814–821.
    1. Rafey MA. Resistant hypertension in the elderly. Clinics in Geriatric Medicine. 2009;25(2):289–301.
    1. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mechanisms of Ageing and Development. 2007;128(1):92–105.
    1. Bartlett DB, Firth CM, Phillips AC, et al. The age-related increase in low-grade systemic inflammation (Inflammaging) is not driven by cytomegalovirus infection. Aging Cell. 2012;11(5):912–915.
    1. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2008;93(9):3266–3281.
    1. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clinical Cardiology. 2008;31(4):153–158.
    1. Luft FC. Mendelian forms of human hypertension and mechanisms of disease. Clinical Medicine & Research. 2003;1(4):291–300.
    1. Zhang Z, Yu Y, Kang Y, Wei S, Felder RB. Aldosterone acts centrally to increase brain renin-angiotensin system activity and oxidative stress in normal rats. The American Journal of Physiology: Heart and Circulatory Physiology. 2008;294(2):H1067–H1074.
    1. Leibovitz E, Ebrahimian T, Paradis P, Schiffrin EL. Aldosterone induces arterial stiffness in absence of oxidative stress and endothelial dysfunction. Journal of Hypertension. 2009;27(11):2192–2200.
    1. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of Physiology: Heart and Circulatory Physiology. 2002;283(5):H1802–H1810.
    1. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. The American Journal of Pathology. 2002;161(5):1773–1781.
    1. Kasal DA, Barhoumi T, Li MW, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension. 2012;59(2):324–330.
    1. Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney International. 2003;63(5):1791–1800.
    1. Tzamou V, Vyssoulis G, Karpanou E, Kyvelou S-, Gialernios T, Stefanadis C. Aldosterone levels and inflammatory stimulation in essential hypertensive patients. Journal of Human Hypertension. 2013;27(9):535–538.
    1. Rodríguez-Iturbe B, Quiroz Y, Nava M, et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. The American Journal of Physiology: Renal Physiology. 2002;282(2):F191–F201.
    1. Tian N, Gu J-W, Jordan S, Rose RA, Hughson MD, Manning RD., Jr. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. The American Journal of Physiology—Heart and Circulatory Physiology. 2007;292(2):H1018–H1025.
    1. Mattson DL, James L, Berdan EA, Meister CJ. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. Hypertension. 2006;48(1):149–156.
    1. Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. Journal of the American Society of Nephrology. 2006;17(12) supplement 3:S218–S225.
    1. de Miguel C, Guo C, Lund H, Feng D, Mattson DL. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. The American Journal of Physiology—Renal Physiology. 2011;300(3):F734–F742.
    1. Ferro CJ, Edwards NC, Hutchison C, et al. Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. Hypertension Research. 2011;34(1):113–119.
    1. Nataraj C, Oliverio MI, Mannon RB, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. Journal of Clinical Investigation. 1999;104(12):1693–1701.
    1. Tissot AC, Maurer P, Nussberger J, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. The Lancet. 2008;371(9615):821–827.
    1. Chen X, Qiu Z, Yang S, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. Hypertension. 2013;61(2):408–416.
    1. Michel J-B, Guettier C, Philippe M, Galen FX, Corvol P, Ménard J. Active immunization against renin in normotensive marmoset. Proceedings of the National Academy of Sciences of the United States of America. 1987;84(12):4346–4350.
    1. Tepperman E, Ramzy D, Prodaer J, et al. Surgical biology forthe clinician: vascular effects of immunosuppression. Canadian Journal of Surgery. 2010;53(1):57–63.
    1. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Annals of Internal Medicine. 1994;121(4):289–300.
    1. Myat A, Redwood SR, Qureshi AC, Spertus Director JA, Williams B. Resistant hypertension. BMJ. 2012;345(7884)e7473
    1. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012;125(13):1594–1596.
    1. Strazzullo P, Kerry SM, Barbato A, Versiero M, D'Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension. 2007;49(4):792–798.
    1. Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108(13):1560–1566.
    1. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine. 2008;359(21):2195–2207.
    1. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Reviews Drug Discovery. 2003;2(7):517–526.
    1. Iwata A, Shirai R, Ishii H, et al. Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells. Clinical and Experimental Immunology. 2012;168(2):234–240.
    1. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. Journal of Biological Chemistry. 1998;273(37):24266–24271.
    1. Lu T-M, Ding Y-A, Leu H-B, Yin W-H, Sheu WH-H, Chu K-M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. The American Journal of Cardiology. 2004;94(2):157–161.
    1. Antoniades C, Shirodaria C, Leeson P, et al. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. European Heart Journal. 2009;30(9):1142–1150.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する